Tirzepatide Tirzepatide is a metabolic research compound commonly evaluated in studies focused on GLP-1 and GIP receptor pathway research
Managements stated focus is now on debt paydown and integrating its recent purchases
Finally, reliable after-sales support is crucial
The drug, Ojemda, is also the only systemic treatment option for pLGG that allows for a once-weekly treatment schedule, according to the company
Other side effects that may occur less frequently include: Fatigue or low energy during early dose adjustment Headaches, often linked to reduced calorie intake Mild dizziness, particularly if meals are skipped Injection-site redness or sensitivity Mounjaro is intentionally started at a low dose during the first month to minimise side effects and support safe adjustment
In 2024 and 2025 the MHRA seized millions of doses of illicit weight-loss injections in the UK, including unbranded retatrutide and research peptides marketed under generic names